Suppliers and packagers for FOSAMAX PLUS D

FOSAMAX PLUS D

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Organon Llc	FOSAMAX PLUS D	alendronate sodium; cholecalciferol	TABLET;ORAL	021762	NDA	Organon LLC	78206-136-01	4 TABLET in 1 BLISTER PACK (78206-136-01)	2021-06-01
Organon Llc	FOSAMAX PLUS D	alendronate sodium; cholecalciferol	TABLET;ORAL	021762	NDA	Organon LLC	78206-137-01	4 TABLET in 1 BLISTER PACK (78206-137-01)	2021-06-01

Suppliers for the Pharmaceutical Drug: FOSAMAX PLUS D

Last updated: August 2, 2025

Introduction

FOSAMAX PLUS D, marketed primarily for the treatment of osteoporosis and related bone health conditions, combines alendronate sodium with vitamin D3. As a leading bisphosphonate therapy, it is widely prescribed globally. Ensuring supply chain security involves identifying reliable manufacturers and suppliers that meet regulatory and quality standards. This article delineates key suppliers for FOSAMAX PLUS D, addressing manufacturing sources, regional production hubs, and the strategic importance of these suppliers within the global pharmaceutical landscape.

Active Pharmaceutical Ingredient (API) Suppliers for FOSAMAX PLUS D

The efficacy and safety profile of FOSAMAX PLUS D hinges critically on the quality of its API components: alendronate sodium and vitamin D3. The supply chain for these ingredients is predominantly concentrated among a handful of large, certified manufacturers adhering to stringent Good Manufacturing Practices (GMP).

Alendronate Sodium Suppliers

Multiple pharmaceutical-grade API manufacturers produce alendronate sodium, a non-proprietary compound available to global pharmaceutical companies. Leading suppliers include:

• Teva Pharmaceutical Industries Ltd.: An Israel-based manufacturer, Teva supplies high-quality alendronate sodium API globally, supported by extensive GMP certification and robust R&D capabilities. Their manufacturing facilities in Israel and India are recognized for consistency and compliance with international standards.

• Merein Pharma Co., Ltd.: Based in China, Meerin Pharma specializes in bisphosphonate APIs. The company's facilities hold certifications from the Food and Drug Administration (FDA) and other regional regulatory bodies, positioning them as reliable sources for alendronate sodium.

• Zhejiang Huahai Pharmaceutical Co., Ltd.: This Chinese firm supplies alendronate sodium with a strong export footprint. Their manufacturing adheres to GMP and they have obtained requisite regulatory approvals for their APIs in multiple markets.

• Mitsubishi Tanabe Pharma Corporation: A Japanese manufacturer providing APIs with high purity standards. Their rigorous quality control procedures ensure consistent product specifications.

Vitamin D3 Suppliers

Vitamin D3 (cholecalciferol) is produced by several reputable API manufacturers:

• DSM Nutritional Products: A leading global supplier, DSM’s vitamin D3 manufacturing uses fermentation-based processes ensuring high purity. Their facilities are certified under GMP, and they supply to multiple pharmaceutical companies.

• Langfords Ltd.: Based in the UK, Langfords produces pharmaceutical-grade vitamin D3 compliant with pharmacopeial standards (USP, EP). Their production processes emphasize purity and stability.

• Gayatri Biosystems Pvt. Ltd.: An Indian manufacturer offering high-quality vitamin D3 for pharmaceutical use, certified by WHO-GMP standards and supporting global export demands.

Formulation and Final Product Manufacturers

Once the APIs are procured, the final FOSAMAX PLUS D tablets are manufactured by various pharmaceutical firms, many of which are authorized licensees or contract manufacturing organizations (CMOs):

• Novartis AG: Originally developed, marketed, and licensed FOSAMAX PLUS D, Novartis maintains strict control over its formulation and manufacturing processes. The company operates manufacturing facilities across Europe and Asia, ensuring product quality and supply chain integrity.

• Sandoz (a Novartis division): Specializing in generics, Sandoz produces FOSAMAX PLUS D under licensing agreements, often sourcing APIs from approved suppliers mentioned above.

• Contract Manufacturing Organizations (CMOs): Numerous CMOs across India, China, and Eastern Europe produce FOSAMAX PLUS D tablets under license agreements or as part of supply chain partnerships with originator companies. These CMOs adhere to rigorous GMP standards, with facilities certified by regulatory agencies like the US FDA, EMA, and WHO.

Regional Supply Chain Dynamics

The global supply chain for FOSAMAX PLUS D reflects regional dynamics:

• Asia-Pacific: China and India dominate API manufacturing, benefiting from cost efficiencies and rapid innovation cycles. Asia-based CMOs also manufacture finished dosage forms for export.

• Europe: European manufacturers like Novartis retain control over formulation and distribution, with some APIs sourced from Asia.

• United States: The US market primarily imports APIs from Asia, with some domestic formulation capacities, although FOSAMAX PLUS D is generally marketed via global licenses.

Regulatory and Quality Standards

Reliable suppliers must comply with regulatory standards such as the US FDA's cGMP, EMA guidelines, and WHO prequalification, which ensure API safety, efficacy, and quality. Certification and documentation of quality are critical for selecting suppliers, especially in the context of global supply chain disruptions.

Strategic Considerations for Stakeholders

• Supply chain resilience: Diversifying API sources from multiple qualified suppliers mitigates risks of shortages.

• Regulatory compliance: Ensuring suppliers maintain current certifications under GMP and meet regional regulatory requirements.

• Cost-effectiveness: Balancing quality standards with cost considerations, particularly in high-volume markets.

• Contractual arrangements: Establishing long-term agreements with key vendors to secure continuous supply.

Conclusion

The supply ecosystem of FOSAMAX PLUS D encompasses a global network of API manufacturers, formulation plants, and licensing partners. Major API producers like Teva, Mitsubishi Tanabe, DSM, and Langfords serve as primary sources, supported by regional manufacturing hubs in China and India. The integrity of this supply chain and adherence to regulatory standards underpin the consistent availability and quality of FOSAMAX PLUS D worldwide.

Key Takeaways

• Leading API suppliers for FOSAMAX PLUS D include Teva, Mitsubishi Tanabe, DSM, and Langfords, each adhering to international GMP standards.
• Asia-Pacific remains the dominant hub for API production, offering cost-effective solutions without compromising quality.
• European and Japanese manufacturers support high-purity standards essential for global markets.
• Regulatory compliance and ongoing quality assurance are vital in supplier selection to eliminate risks of substandard APIs.
• Diversification of suppliers and strategic agreements are critical for ensuring uninterrupted supply amid global disruptions.

FAQs

1. Who are the primary manufacturers of alendronate sodium API used in FOSAMAX PLUS D?
Major producers include Teva Pharmaceutical Industries, Mitsubishi Tanabe Pharma, Zhejiang Huahai Pharmaceutical, and Meerin Pharma, all complying with GMP and international standards.

2. What regions dominate the supply of vitamin D3 for FOSAMAX PLUS D?
China, India, and Europe are key regions, with companies like DSM and Langfords providing pharmaceutical-grade vitamin D3.

3. How do regulatory standards impact supplier selection?
Suppliers must meet GMP requirements from agencies like the US FDA, EMA, and WHO prequalification standards, ensuring API safety and quality.

4. Are there regional differences in FOSAMAX PLUS D manufacturing?
Yes, while API procurement is often regionally concentrated, finished formulations are manufactured worldwide through licensed partners and CMOs across Europe, Asia, and North America.

5. What risks exist in the supply of FOSAMAX PLUS D, and how can they be mitigated?
Risks include supply disruptions, regulatory non-compliance, and quality lapses. These can be mitigated through supplier diversification, rigorous qualification processes, and long-term contractual agreements.

---

Sources:

1. [1] Global sources of alendronate sodium API — Novartis corporate disclosures.
2. [2] API manufacturing standards — WHO, EMA, FDA regulatory guidelines.
3. [3] Industry reports on vitamin D3 global production — DSM, Langfords, and market analyses.
4. [4] Contract manufacturing insights in the pharmaceutical industry.